91.69 USD
+1.15 (+1.27%)
91.69 USD
0 (0%)
AZN gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. AZN scores excellent on profitability, but there are some minor concerns on its financial health. AZN has a decent growth rate and is not valued too expensively. Finally AZN also has an excellent dividend rating.
1. Profitability
1.1 Basic Checks
- In the past year AZN was profitable.
- AZN had a positive operating cash flow in the past year.
- AZN had positive earnings in each of the past 5 years.
- Each year in the past 5 years AZN had a positive operating cash flow.
1.2 Ratios
- With an excellent Return On Assets value of 8.21%, AZN belongs to the best of the industry, outperforming 89.53% of the companies in the same industry.
- With an excellent Return On Equity value of 20.48%, AZN belongs to the best of the industry, outperforming 90.58% of the companies in the same industry.
- AZN has a better Return On Invested Capital (14.42%) than 93.72% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for AZN is in line with the industry average of 12.84%.
- The 3 year average ROIC (11.62%) for AZN is below the current ROIC(14.42%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.21% | ||
| ROE | 20.48% | ||
| ROIC | 14.42% |
ROA(3y)5.35%
ROA(5y)4.19%
ROE(3y)13.78%
ROE(5y)12.42%
ROIC(3y)11.62%
ROIC(5y)9.52%
1.3 Margins
- AZN has a Profit Margin of 16.17%. This is amongst the best in the industry. AZN outperforms 88.48% of its industry peers.
- In the last couple of years the Profit Margin of AZN has grown nicely.
- AZN has a Operating Margin of 24.34%. This is amongst the best in the industry. AZN outperforms 91.10% of its industry peers.
- In the last couple of years the Operating Margin of AZN has grown nicely.
- AZN has a better Gross Margin (81.90%) than 85.34% of its industry peers.
- AZN's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 24.34% | ||
| PM (TTM) | 16.17% | ||
| GM | 81.9% |
OM growth 3Y21.43%
OM growth 5Y8.6%
PM growth 3Y251.6%
PM growth 5Y18.9%
GM growth 3Y3.31%
GM growth 5Y0.47%
2. Health
2.1 Basic Checks
- AZN has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
- The number of shares outstanding for AZN remains at a similar level compared to 1 year ago.
- AZN has more shares outstanding than it did 5 years ago.
- AZN has a worse debt/assets ratio than last year.
2.2 Solvency
- An Altman-Z score of 3.45 indicates that AZN is not in any danger for bankruptcy at the moment.
- AZN has a Altman-Z score of 3.45. This is in the better half of the industry: AZN outperforms 66.49% of its industry peers.
- The Debt to FCF ratio of AZN is 3.41, which is a good value as it means it would take AZN, 3.41 years of fcf income to pay off all of its debts.
- AZN's Debt to FCF ratio of 3.41 is amongst the best of the industry. AZN outperforms 87.43% of its industry peers.
- A Debt/Equity ratio of 0.61 indicates that AZN is somewhat dependend on debt financing.
- AZN's Debt to Equity ratio of 0.61 is on the low side compared to the rest of the industry. AZN is outperformed by 68.06% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.61 | ||
| Debt/FCF | 3.41 | ||
| Altman-Z | 3.45 |
ROIC/WACC1.64
WACC8.8%
2.3 Liquidity
- AZN has a Current Ratio of 0.88. This is a bad value and indicates that AZN is not financially healthy enough and could expect problems in meeting its short term obligations.
- Looking at the Current ratio, with a value of 0.88, AZN is doing worse than 87.43% of the companies in the same industry.
- AZN has a Quick Ratio of 0.88. This is a bad value and indicates that AZN is not financially healthy enough and could expect problems in meeting its short term obligations.
- The Quick ratio of AZN (0.69) is worse than 86.39% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.88 | ||
| Quick Ratio | 0.69 |
3. Growth
3.1 Past
- AZN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 20.61%, which is quite impressive.
- The Earnings Per Share has been growing by 18.59% on average over the past years. This is quite good.
- Looking at the last year, AZN shows a quite strong growth in Revenue. The Revenue has grown by 13.52% in the last year.
- The Revenue has been growing by 17.27% on average over the past years. This is quite good.
EPS 1Y (TTM)20.61%
EPS 3Y15.85%
EPS 5Y18.59%
EPS Q2Q%14.42%
Revenue 1Y (TTM)13.52%
Revenue growth 3Y13.06%
Revenue growth 5Y17.27%
Sales Q2Q%11.99%
3.2 Future
- The Earnings Per Share is expected to grow by 12.37% on average over the next years. This is quite good.
- The Revenue is expected to grow by 7.20% on average over the next years.
EPS Next Y11.95%
EPS Next 2Y12.55%
EPS Next 3Y12.2%
EPS Next 5Y12.37%
Revenue Next Year10.2%
Revenue Next 2Y8.11%
Revenue Next 3Y7.34%
Revenue Next 5Y7.2%
3.3 Evolution
- The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 19.93, which indicates a rather expensive current valuation of AZN.
- Compared to the rest of the industry, the Price/Earnings ratio of AZN indicates a rather cheap valuation: AZN is cheaper than 82.20% of the companies listed in the same industry.
- AZN's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.32.
- The Price/Forward Earnings ratio is 17.51, which indicates a rather expensive current valuation of AZN.
- Based on the Price/Forward Earnings ratio, AZN is valued a bit cheaper than 79.58% of the companies in the same industry.
- The average S&P500 Price/Forward Earnings ratio is at 24.32. AZN is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.93 | ||
| Fwd PE | 17.51 |
4.2 Price Multiples
- 82.72% of the companies in the same industry are more expensive than AZN, based on the Enterprise Value to EBITDA ratio.
- Based on the Price/Free Cash Flow ratio, AZN is valued cheaper than 81.15% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 29.72 | ||
| EV/EBITDA | 14.65 |
4.3 Compensation for Growth
- AZN's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
- The excellent profitability rating of AZN may justify a higher PE ratio.
- A more expensive valuation may be justified as AZN's earnings are expected to grow with 12.20% in the coming years.
PEG (NY)1.67
PEG (5Y)1.07
EPS Next 2Y12.55%
EPS Next 3Y12.2%
5. Dividend
5.1 Amount
- With a Yearly Dividend Yield of 1.74%, AZN has a reasonable but not impressive dividend return.
- Compared to an average industry Dividend Yield of 0.40, AZN pays a better dividend. On top of this AZN pays more dividend than 91.62% of the companies listed in the same industry.
- Compared to an average S&P500 Dividend Yield of 1.83, AZN has a dividend comparable with the average S&P500 company.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.74% |
5.2 History
- The dividend of AZN has a limited annual growth rate of 1.40%.
- AZN has been paying a dividend for at least 10 years, so it has a reliable track record.
- AZN has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.
Dividend Growth(5Y)1.4%
Div Incr Years1
Div Non Decr Years11
5.3 Sustainability
- AZN pays out 52.89% of its income as dividend. This is a bit on the high side, but may be sustainable.
- The dividend of AZN is growing, but earnings are growing more, so the dividend growth is sustainable.
DP52.89%
EPS Next 2Y12.55%
EPS Next 3Y12.2%
91.69
+1.15 (+1.27%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06 2025-11-06/bmo
Earnings (Next)02-10 2026-02-10/amc
Inst Owners49.17%
Inst Owner Change0.41%
Ins Owners0.02%
Ins Owner ChangeN/A
Market Cap284.29B
Revenue(TTM)58.13B
Net Income(TTM)9.40B
Analysts82.42
Price Target97.79 (6.65%)
Short Float %0.37%
Short Ratio1.68
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.74% |
Yearly Dividend2.99
Dividend Growth(5Y)1.4%
DP52.89%
Div Incr Years1
Div Non Decr Years11
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.14%
Min EPS beat(2)-1.74%
Max EPS beat(2)1.47%
EPS beat(4)2
Avg EPS beat(4)2.1%
Min EPS beat(4)-1.74%
Max EPS beat(4)9.32%
EPS beat(8)4
Avg EPS beat(8)0.88%
EPS beat(12)8
Avg EPS beat(12)2.53%
EPS beat(16)12
Avg EPS beat(16)3.75%
Revenue beat(2)0
Avg Revenue beat(2)-0.25%
Min Revenue beat(2)-0.26%
Max Revenue beat(2)-0.24%
Revenue beat(4)1
Avg Revenue beat(4)-0.45%
Min Revenue beat(4)-3.99%
Max Revenue beat(4)2.7%
Revenue beat(8)3
Avg Revenue beat(8)0.07%
Revenue beat(12)4
Avg Revenue beat(12)-0.52%
Revenue beat(16)6
Avg Revenue beat(16)0.18%
PT rev (1m)1.82%
PT rev (3m)8.16%
EPS NQ rev (1m)1.62%
EPS NQ rev (3m)-1.3%
EPS NY rev (1m)-1.9%
EPS NY rev (3m)-1.45%
Revenue NQ rev (1m)-0.03%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0.07%
Revenue NY rev (3m)0.52%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.93 | ||
| Fwd PE | 17.51 | ||
| P/S | 4.89 | ||
| P/FCF | 29.72 | ||
| P/OCF | 18.78 | ||
| P/B | 6.2 | ||
| P/tB | N/A | ||
| EV/EBITDA | 14.65 |
EPS(TTM)4.6
EY5.02%
EPS(NY)5.24
Fwd EY5.71%
FCF(TTM)3.09
FCFY3.37%
OCF(TTM)4.88
OCFY5.33%
SpS18.75
BVpS14.8
TBVpS-4.36
PEG (NY)1.67
PEG (5Y)1.07
Graham Number39.14
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.21% | ||
| ROE | 20.48% | ||
| ROCE | 17.6% | ||
| ROIC | 14.42% | ||
| ROICexc | 16.02% | ||
| ROICexgc | 81.56% | ||
| OM | 24.34% | ||
| PM (TTM) | 16.17% | ||
| GM | 81.9% | ||
| FCFM | 16.46% |
ROA(3y)5.35%
ROA(5y)4.19%
ROE(3y)13.78%
ROE(5y)12.42%
ROIC(3y)11.62%
ROIC(5y)9.52%
ROICexc(3y)12.66%
ROICexc(5y)10.55%
ROICexgc(3y)112.76%
ROICexgc(5y)85.06%
ROCE(3y)13.95%
ROCE(5y)11.45%
ROICexgc growth 3Y43.28%
ROICexgc growth 5Y4.77%
ROICexc growth 3Y41%
ROICexc growth 5Y11.99%
OM growth 3Y21.43%
OM growth 5Y8.6%
PM growth 3Y251.6%
PM growth 5Y18.9%
GM growth 3Y3.31%
GM growth 5Y0.47%
F-Score7
Asset Turnover0.51
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.61 | ||
| Debt/FCF | 3.41 | ||
| Debt/EBITDA | 1.34 | ||
| Cap/Depr | 84.97% | ||
| Cap/Sales | 9.59% | ||
| Interest Coverage | 10.83 | ||
| Cash Conversion | 73.11% | ||
| Profit Quality | 101.79% | ||
| Current Ratio | 0.88 | ||
| Quick Ratio | 0.69 | ||
| Altman-Z | 3.45 |
F-Score7
WACC8.8%
ROIC/WACC1.64
Cap/Depr(3y)61.87%
Cap/Depr(5y)60.41%
Cap/Sales(3y)7.51%
Cap/Sales(5y)7.64%
Profit Quality(3y)144.6%
Profit Quality(5y)772.45%
High Growth Momentum
Growth
EPS 1Y (TTM)20.61%
EPS 3Y15.85%
EPS 5Y18.59%
EPS Q2Q%14.42%
EPS Next Y11.95%
EPS Next 2Y12.55%
EPS Next 3Y12.2%
EPS Next 5Y12.37%
Revenue 1Y (TTM)13.52%
Revenue growth 3Y13.06%
Revenue growth 5Y17.27%
Sales Q2Q%11.99%
Revenue Next Year10.2%
Revenue Next 2Y8.11%
Revenue Next 3Y7.34%
Revenue Next 5Y7.2%
EBIT growth 1Y26.07%
EBIT growth 3Y37.28%
EBIT growth 5Y27.35%
EBIT Next Year32.31%
EBIT Next 3Y16.96%
EBIT Next 5Y13.82%
FCF growth 1Y37.12%
FCF growth 3Y24.58%
FCF growth 5Y70.22%
OCF growth 1Y46.1%
OCF growth 3Y25.76%
OCF growth 5Y31.92%
ASTRAZENECA PLC-SPONS ADR / AZN FAQ
Can you provide the ChartMill fundamental rating for ASTRAZENECA PLC-SPONS ADR?
ChartMill assigns a fundamental rating of 6 / 10 to AZN.
What is the valuation status for AZN stock?
ChartMill assigns a valuation rating of 6 / 10 to ASTRAZENECA PLC-SPONS ADR (AZN). This can be considered as Fairly Valued.
How profitable is ASTRAZENECA PLC-SPONS ADR (AZN) stock?
ASTRAZENECA PLC-SPONS ADR (AZN) has a profitability rating of 9 / 10.
Can you provide the PE and PB ratios for AZN stock?
The Price/Earnings (PE) ratio for ASTRAZENECA PLC-SPONS ADR (AZN) is 19.93 and the Price/Book (PB) ratio is 6.2.
What is the expected EPS growth for ASTRAZENECA PLC-SPONS ADR (AZN) stock?
The Earnings per Share (EPS) of ASTRAZENECA PLC-SPONS ADR (AZN) is expected to grow by 11.95% in the next year.